Beyond Circulating Tumor Cell Enumeration: Cell-Based Liquid Biopsy to Assess Protein Biomarkers and Cancer Genomics Using the RareCyte<sup>®</sup> Platform.

Kaldjian, Eric P; Ramirez, Arturo B; Costandy, Lillian; Ericson, Nolan G; Malkawi, Walla I; George, Thaddeus C; Kasi, Pashtoon Murtaza

Beyond Circulating Tumor Cell Enumeration: Cell-Based Liquid Biopsy to Assess Protein Biomarkers and Cancer Genomics Using the RareCyte^® Platform.

Kaldjian, Eric P; Ramirez, Arturo B; Costandy, Lillian; Ericson, Nolan G; Malkawi, Walla I; George, Thaddeus C; Kasi, Pashtoon Murtaza.

Afiliação

Kaldjian EP; RareCyte, Inc, Seattle, WA, United States.
Ramirez AB; RareCyte, Inc, Seattle, WA, United States.
Costandy L; RareCyte, Inc, Seattle, WA, United States.
Ericson NG; RareCyte, Inc, Seattle, WA, United States.
Malkawi WI; Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, United States.
George TC; RareCyte, Inc, Seattle, WA, United States.
Kasi PM; Division of Internal Medicine, Department of Hematology and Oncology, Weill Cornell Medicine, New York, NY, United States.

Front Pharmacol ; 13: 835727, 2022.

Article em En | MEDLINE | ID: mdl-35308236

Palavras-chave

circulating tumor cell; companion diagnostics; drug target; liquid biopsy; pharmacodynamics; protein biomarker; resistance phenotype; single cell sequencing

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article